Transcription of PRESS RELEASE - M2 Computing
{{id}} {{{paragraph}}}
Example: air traffic controller
PRESS RELEASE - M2 Computing
PRESS RELEASE PAM 093 Issue 00 P First subject enrolled in Veryan Medical s MIMICS-2 study 29 June 2015 Veryan Medical has announced that the first subject was enrolled today in their MIMICS-2 study at Universit ts-Herzzentrum freiburg in Bad Krozingen, Germany by the European Principal Investigator, Professor Thomas Zeller. MIMICS-2 is a prospective, single-arm, multicenter clinical trial of the BioMimics 3D Stent System being conducted under US Investigational Device Exemption (IDE) approved by FDA, which will enroll 280 subjects in up to 40 sites in the US and Germany. The US Principal Investigator is Timothy Sullivan, MD, Chairman of Vascular/Endovascular Surgery at Minneapolis Heart Institute at Abbott Northwestern Hospital. The purpose of MIMICS-2 is to provide data to support a US Premarket Approval Application (PMA). It will evaluate the BioMimics 3D Stent System against the performance goals defined by VIVA Physicians, Inc.
PRESS RELEASE PAM 093 Issue 00 P First subject enrolled in Veryan Medical’s MIMICS-2 study 29 June 2015 – Veryan Medical has announced that the first subject was enrolled today in their MIMICS-2 study at Universitäts-Herzzentrum Freiburg in Bad
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: